Printer Friendly

Ajinomoto, Astellas Pharma Jointly File Application Seeking Additional Approval for Combination Therapy of FASTIC/STARSIS Tablets, Fast-acting Postprandial Hypoglycemic Agent, with Biguanide.

Tokyo, Japan, Jan 30, 2006 - (JCN) - Ajinomoto and Astellas Pharma jointly announced on January 27 that they have filed a supplemental New Drug Application (SNDA) for FASTIC Tablet/STARSIS Tablet (nateglinide), a fast-acting postprandial hypoglycemic agent co-developed by the two companies.

The two companies expect approval for combination therapy of FASTCI/STARSIS with biguanide agents. Nateglinide, which is an amino acid derivative, is an oral hypoglycemic agent launched in August 1999.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 1, 2006
Words:81
Previous Article:Chugai Pharmaceutical Renovates Its Website for Actemra, Drug for the Castleman's Disease.
Next Article:Sysmex America, ACL Laboratories Collaborate in Hematology Analysis.


Related Articles
Eisai to Distribute Actonel Osteoporosis Treatment for Ajinomoto.
Astellas Pharma, XenoPort Conclude Licensing Agreement for XP13512 Analgesic Agent.
Astellas Pharma Submits NDA for FK506 Immunosuppressant to FDA.
Astellas Pharma Receives FDA Approval for Hyponatremia Drug VAPRISOL.
Astellas Pharma, Toyama Chemical Agree on Joint Development of Quinolone Antibiotic T-3811 in Japan.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Astellas Pharma Obtains Approval for Funguard and Vesicare.
Ajinomoto, Sankyo in Joint Development, Manufacture and Marketing of AJD101, New Diabetes Drug.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters